Management of cutaneous locoregional recurrences of melanoma: A new therapeutic perspective with imiquimod [1]

Dermatology

Volumn 206, Issue 3, 2003, Pages 279-280

  Vereecken, Pierre ^a,b,d   Mathieu, Anne ^a   Laporte, Marianne ^a   Petein, Michel ^c   Velu, Thierry ^a   Awada, Ahmad ^b   Heenen, Michel ^a  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^d NONE   (Belgium)

Author keywords

Imiquimod; In transit metastases; Melanoma

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CYTOKINE; GAMMA INTERFERON; IMIQUIMOD; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

AGED; BRACHYTHERAPY; CASE REPORT; CRYOSURGERY; DRUG EFFECT; ELECTROSURGERY; FEMALE; HUMAN; LASER SURGERY; LETTER; LYMPHADENECTOMY; MELANOMA; METASTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; SCAR; SKIN IRRITATION; SYSTEMIC DISEASE;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 0037246514     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068901     Document Type: Letter

References (12)

1. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW: Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-69.
2. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A Jr, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-1491.
3. Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL: Natural history and selective management of in transit melanoma. J Surg Oncol 1990;44: 146-150.
4. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA: Local recurrence in malignant melanoma: Long term results of the multiinstitutional randomised surgical trial. Ann Surg Oncol 1996;3:446-452.
5. Dummer R, Bösch U, Panizzon R, Bloch PH, Burg G: Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001; 203:75-80.
6. Brochez L, Verhaeghe E, Sales F, Del Marmol V, Deraemaecker R, Vossaert K, Naeyaert JM: Current guidelines in melanoma treatment. Dermatology 2000;200:160-166.
7. Edwards L: Imiquimod in clinical practice. J Am Acad Dermatol 2000; 43(1, pt 2):S12-S17.
8. Dahl MV: Imiquimod: An immune response modifier. J Am Acad Dermatol 2000;43(1, pt 2):S1-S5.
9. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, Owens ML: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-813.
10. Hengge UR, Stark R: Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001;137:709-711.
11. Steinmann A, Funk JO, Schuler G. von den Driesch P: Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-556.
12. Sauder DN: Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43(1, pt 2):S6-S11.